TuHURA Biosciences, Inc. (HURA)
0.8868
+0.02
(+1.93%)
USD |
NASDAQ |
Dec 18, 16:00
0.9067
+0.02
(+2.24%)
After-Hours: 06:15
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 50.08M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -77.94% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 3.036 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0344 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.97% |
Profile
| TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded on May 4, 2023 and is headquartered in Tampa, FL. |
| URL | http://www.tuhurabio.com |
| Investor Relations URL | https://tuhurabio.com/investors/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Nov. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded on May 4, 2023 and is headquartered in Tampa, FL. |
| URL | http://www.tuhurabio.com |
| Investor Relations URL | https://tuhurabio.com/investors/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Nov. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |